B. Braun将其肝素钠注射液产品线扩展至七种肝素预混钠注射产品-动脉网

B. Braun Expands Heparin Sodium Injection Portfolio to Seven Heparin Premixed Sodium Injection Products

CISION 等信源发布 2025-07-18 21:34



可切换为仅中文







BETHLEHEM, Pa.

伯利恒，宾夕法尼亚州

，

July 18, 2025

2025年7月18日

/PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, announced today the launch of its new Heparin Sodium Injections into the U.S. market, expanding its portfolio to include 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL).

/PRNewswire/ -- B. Braun Medical Inc.（B. Braun），智能输液治疗和疼痛管理领域的领导者，今天宣布在美国市场推出其新的肝素钠注射液，扩展了其产品组合，包括25,000单位肝素在0.45%氯化钠注射液中（50单位/mL）和25,000单位肝素在0.45%氯化钠注射液中（100单位/mL）。

These launches expand B. Braun's portfolio to become the largest offering of Heparin Premixed bags in the U.S. market. The 250 mL and 500 mL bags will feature a 2D enhanced barcode. The 2D enhanced barcode design includes the National Drug Code (NDC) number, lot number and expiration date, along with increased spacing between the two 1D barcodes.

这些产品的推出扩充了B. Braun的产品组合，使其成为美国市场上海量预混肝素袋的最大供应商。250毫升和500毫升的袋子将带有二维增强型条形码。该二维增强型条形码设计包含国家药品代码（NDC）编号、批号和有效期，并且两个一维条形码之间的间距也有所增加。

These enhancements are designed to help improve the accuracy and efficiency of barcode scanning..

这些增强功能旨在帮助提高条形码扫描的准确性和效率。

The B. Braun Heparin portfolio is manufactured using EXCEL

贝朗肝素产品组合采用EXCEL制造。

IV Containers, which are not made with DEHP, PVC or natural rubber latex, prioritizing patient and environmental safety. The product is produced and distributed from B. Braun's

IV容器，未使用DEHP、PVC或天然橡胶乳胶制成，优先考虑患者和环境安全。该产品由B. Braun生产并分销。

Irvine, California

加利福尼亚州，尔湾市

pharmaceutical manufacturing facility.

制药生产设施。

'Expanding our Heparin Sodium Injection portfolio underscores our commitment to healthcare providers and their patients. By offering the largest selection of premixed Heparin products in the market, we are helping to provide healthcare workers with the tools they need to deliver precise and effective care,' said .

“扩展我们的肝素钠注射液产品组合，彰显了我们对医疗保健提供者及其患者的承诺。通过提供市场上种类最全的预混肝素产品，我们正在帮助为医疗工作者提供他们所需的工具，以提供精确且有效的护理，”该公司表示。

Shawn Brinson

肖恩·布林森

, Director of Marketing, Injectable Drugs, B. Braun Medical Inc.

，市场总监，注射药物，贝朗医疗公司。

Heparin Sodium 25,000 Units Heparin in 0.45% Sodium Chloride Injection (50 units/mL) and Heparin Sodium 25,000 Units Heparin in 0.45% Sodium Chloride Injection (100 units/mL), are indicated as anticoagulants to maintain catheter patency.

肝素钠 25,000 单位肝素在 0.45% 氯化钠注射液（50 单位/毫升）和肝素钠 25,000 单位肝素在 0.45% 氯化钠注射液（100 单位/毫升）中，用作抗凝剂以保持导管通畅。

For additional information, please see full

有关更多信息，请参阅完整内容

Prescribing Information

处方信息

。

IMPORTANT SAFETY INFORMATION

重要安全信息

Contraindications:

禁忌症：

History of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis (HITT)

肝素诱导的血小板减少症（HIT）或肝素诱导的血小板减少症和血栓形成（HITT）病史

Known hypersensitivity to heparin or pork products (e.g., anaphylactoid reactions)

已知对肝素或猪肉产品过敏（例如，类过敏反应）

In whom suitable blood coagulation tests — e.g., the whole blood clotting time, partial thromboplastin time, etc., — cannot be performed at appropriate intervals (this contraindication refers to full-dose heparin; there is usually no need to monitor coagulation parameters in patients receiving low-dose heparin).

对于不能按适当间隔进行合适的血液凝固试验（如全血凝固时间、部分凝血活酶时间等）的患者（此禁忌症指全剂量肝素；通常无需监测接受低剂量肝素患者的凝血参数）。

Uncontrollable active bleeding state except when this is due to disseminated intravascular coagulation

无法控制的活动性出血状态，除非这是由于弥散性血管内凝血引起的。

About B. Braun

关于B. Braun

B. Braun Medical Inc. (B. Braun) is a leader in smart infusion therapy and safe and effective pharmacy products, patient and provider safety, and sustainable health solutions. Our purpose is to help providers constantly improve patient satisfaction and outcomes. With products and services created to help healthcare professionals focus on what matters most—their patients—we're uniquely positioned to help health systems succeed now and in the future.

B. Braun Medical Inc.（B. Braun）是智能输液治疗、安全有效的药房产品、患者和供应商安全以及可持续健康解决方案的领导者。我们的宗旨是帮助供应商不断提高患者的满意度和治疗效果。通过为医疗专业人员设计的产品和服务，让他们专注于最重要的事情——他们的患者，我们有能力帮助医疗系统现在和未来取得成功。

B. Braun is headquartered in .

B. Braun 总部位于。

Bethlehem, Pennsylvania

伯利恒，宾夕法尼亚州

and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap

是美国B. Braun集团公司的组成部分，包括B. Braun介入系统公司、Aesculap公司等。

and CAPS

大写锁定

. The company employs 8,500 people at over 30 locations across

公司在超过30个地点雇用了8500人。

North America

北美

。

Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise

全球范围内，B. Braun集团公司在64个国家拥有超过64,000名员工。公司以“分享专业知识”为指导原则。

philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, explore our

哲学，B. Braun不断与客户、合作伙伴和临床医生交流知识，以解决提高护理水平和降低成本的关键问题。要了解更多关于B. Braun Medical的信息，请访问我们的

website

网站

。

SOURCE B. Braun Medical Inc.

来源：贝朗医疗公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+